Skip to main content
. 2021 Jan 8;11:591134. doi: 10.3389/fphar.2020.591134

TABLE 1.

Adalimumab biosimilars approved by the European Medicines Agency for use in the European Union as of September 2020 (European Medicines Agency, 2020).

Brand name Marketing authorization holder Marketing authorization date
Amgevita® Amgen March 21, 2017
Imraldi® Samsung Bioepis August 24, 2017
Hyrimoz®/Hefiya®/Halimatoz® a Sandoz July 26, 2018
Hulio® Mylan September 16, 2018
Idacio® Fresenius Kabi April 02, 2019
Amsparity® Pfizer February 13, 2020
a

Different brand names might be used as a marketing strategy or to circumvent potential patent issues via different indications on the label.